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Introduction

“The real voyage of discovery consists not in seeking new landscapes, but in having new eyes” – 
Marcel Proust.   
New perspectives can require a paradigm shift, then innovative concepts can arise from incidental 
but penetrating insights. A new disease entity might require new diagnostic and conceptual 
approaches before achieving general acceptance. The establishment of diagnostic criteria is based 
on experience and essential differentiation from similar pathologies and secondary conditions. 
Essential pathophysiological and genetic approaches might lead to novel therapeutic methods that 
could rescue patients from lethal events.  
Hirano et al. identified triglyceride deposit cardiomyovasculopathy (TGCV) in a patient who 
received a heart cardiac transplant in Japan during 2008 [1, 2]. Microscopy revealed atherosclerotic 
triglyceride, rather than cholesterol deposits, in the coronary arteries, and numerous vacuoles in 
cardiomyocytes of the explanted heart. Genetic analysis discovered that the patient harboured a 
mutation in the adipose triglyceride lipase gene. One established cause of TGCV is a genetic 
deficiency of adipose triglyceride lipase that plays a key role in intracellular triglyceride hydrolysis. 
Thus, TGCV was encoded as a rare cardiovascular disorder in Orphanet (ORPHA code: 565612) 
[3]. This editorial discusses how to recognise and diagnose TGCV using current methods and 
provides some suggestions to help understand this rare disease entity.  
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TGCV and atherosclerosis

The principal disorder in TGCV is defective intracellular lipolysis, which causes excessive 
triglyceride accumulation in the myocardium and coronary artery vascular smooth muscle cells, 
leading to heart failure and coronary artery disease with a poor prognosis. 
The total number of patients diagnosed with TGCV in Japan between 2008 and 2014 was < 10 
according to a report published by the Japan TGCV study group [4]. Thereafter, the number 
increased to 226, among whom, 45 were deceased by the end of 2019, indicating a high-risk profile. 
The rapid increase in the number of patients might have been partly due to the fact that the 
diagnostic criteria have piqued public and cardiologist interest in enhancing awareness of TGCV. 
The prevalence of TGCV awareness is low outside of Japan. Diffuse atherosclerotic lesions 
associated with multivessel coronary artery disease should be carefully excluded by identifying 
coronary artery narrowing using coronary CT and coronary angiography. Atherosclerotic lesions 
due to familial hypercholesterolemia can be differentiated by serum lipid profiles. Other disease 
entities that require exclusion include [4]  hypertrophic, dilated, arrhythmogenic right ventricular, 
diabetic, and mitochondrial cardiomyopathies, alcoholic heart disease, metabolic myocardial 
disorders such as Fabry, Pompe, Danon, mitochondrial and cholesteryl ester storage diseases, and a 
CD36 deficiency,  as well as a drug-induced or dialysis-associated carnitine deficiency, and 
excessive epicardial fat deposition.  
Prognosis of TGCV and haemodialysis

Onishi et al. reported the prevalence and prognosis of TGCV among patients on haemodialysis in 
this issue of Heart [5].  The prevalence of nonfatal myocardial infarction, nonfatal stroke or 
cardiovascular death for patients with definitive TGCV was 53% in contrast to patients without 
TGCV (9%). The 20% frequency of definitive TGCV in patients with haemodialysis and suspected 
of having coronary artery disease might have been partly attributed to author selection bias for 123I- 
BMIPP imaging and a diagnosis of diffuse coronary artery narrowing. Thus, whether the frequency 
of TGCV can be extrapolated to patients on haemodialysis in other communities and nations is not 
clear. In addition, their study was based on diagnostic criteria defined in 2016, when myocardial 
triglyceride deposition or impaired LFCA metabolism and diffuse coronary narrowing were 
considered as major components (2 points each), whereas the Jordan anomaly and diabetes were 
considered as minor components (1 point each). Scores of ≥ 4 and 3 were taken as definitive and 
probable TGCV, respectively. The 2020 diagnostic criteria for TGCV include the modifications 
discussed below (Table 1). However, their diagnosis of definitive TGCV would not be changed 
even with the new criteria, and the present study suggests that a diagnostic combination of 123I-
BMIPP and diffuse narrowing of coronary arteries is effective for the diagnosis. 
123I-BMIPP fatty acid imaging

Long-chain fatty acids (LCFA) comprise the major energy source of the normally contracting heart. 
They are incorporated into the cellular triglyceride pool after uptake into cardiomyocytes (Figure 
1A), where enzymes such as adipose triglyceride lipase, hydrolyse triglycerides. Released fatty acid 
is subsequently oxidised in the mitochondria to produce adenosine triphosphate. Metabolic 
processes can be visualised using the unique radiotracer, β-methyl-iodophenylpentadecanoic acid 
(123I-BMIPP). This tracer has been widely applied in Japan since the Ministry of Health and Welfare 
approved 123I-BMIPP with wide indications for cardiac diseases in1993. After uptake into 
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myocytes, 123I-BMIPP is transferred to the triglyceride pool, then to mitochondria, but it is not 
immediately metabolised by β oxidation, due to having branched structures in the beta position. It is 
therefore regarded as a retention-type radiotracer that undergoes slow α oxidation followed by β 
oxidation, which differs from LCFA that are a major cardiac source of energy. However, slow 
clearance from the heart is convenient for nuclear single-photon emission computed tomography 
(SPECT) imaging. Images are obtained early (15 minutes) and late (3–4 hours) after intravenous 
injection of the tracer to calculate washout rates. The average washout rate in 3 hours is 10%–30% 
in coronary artery disease and even under normal conditions. Thus, a low washout rate (< 10%) can 
be an important indicator of TGCV metabolism. While reduced 123I-BMIPP clearance might have a 
diagnostic role in TGCV, BMIPP kinetics are not yet fully understood and are considered to be a 
composite of back diffusion, α and β oxidation, and intermediate metabolites. Since washout can 
vary depending on the algorithm used to calculate it, a standardised method applicable to 
heterogeneous distribution and focal defects should be investigated from a technological viewpoint 
to determine the optimal diagnostic threshold. Figure 1B and C shows typical 123I-BMIPP clearance 
in patients with and without TGCV.  
New diagnostic criteria for TGCV

The revised 2020 diagnostic criteria conformed to this underlying pathophysiology (Table 1) [4]. 
The essential diagnostic criteria comprise metabolic evidence of very slow or absent triglyceride 
clearance from the heart determined as 123I-BMIPP washout rates on myocardial SPECT [6], direct 
histological evidence from biopsy specimens identified in the initial report about the patient [1], and 
evidence of triglyceride deposits determined by X-ray computed tomography (CT) or nuclear 
magnetic resonance (NMR) spectroscopy. The essential items associated with evidence of 
triglyceride deposition in the new guidelines are emphasised, and heart failure has been added. In 
addition, the major criteria include reduced left ventricular contractility associated with heart 
failure, which reflects the experiences of patients with TGCV, during which atypical courses might 
arise. Diffuse narrowing of coronary arteries with triglyceride deposition is also a feature [7]. The 
Jordan anomaly in peripheral blood smears is also diagnostic, although neutral lipid storage disease 
with ichthyosis, and a carnitine palmitoyltransferase deficiency can also cause this anomaly. 
Primary and idiopathic TGCV can be differentially diagnosed based on the presence or absence, 
respectively, of a typical Jordan anomaly. Since TGCV cannot be diagnosed with conventional 
serum triglyceride, cholesterol profiles, and body mass index, the new guidelines should help 
physicians to diagnose TGCV effectively. 
What is the next step?

A new perspective and diagnostic procedures might be required to diagnose new disease entities. 
However, the first step is to become aware of a disease and try to visualise it. Even when diagnosed 
by contemporary techniques, therapeutic intervention will be the next important step. In this 
context, glyceryl decanoate (tricaprin) has been investigated as a nutritional therapeutic agent [8], as 
this medium-chain fatty acid eliminates myocardial triglyceride deposition. A diagnosis of TGCV 
might be more easily promoted using 123I-BMIPP in Japan. However, 123I-BMIPP might also be 
useful for research applications elsewhere, and the feasibility of approaches using X-ray CT and 
NMR spectroscopy should also be investigated to extend diagnostic capabilities worldwide. 
Accumulated experience with TGCV is definitely important to determine the next steps.  
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Table 1 Diagnostic criteria 2020 for triglyceride deposit cardiomyovasculopathy
If imaging protocols for 123I-BMIPP myocardial scintigraphy, cardiac CT and cardiac MR 
spectroscopy are needed, contact Japan TGCV Study Group (E-mail: info@tgcv.org) 
Abbreviations: CAG, coronary angiography; CT, computed tomography; 123I-BMIPP, iodine-123-
β-methyl-iodophenyl-pentadecanoic acid; LCFA, long chain fatty acid; MR, magnetic resonance; 
SPECT, single-photon emission computed tomography; TGCV, triglyceride deposit 
cardiomyovasculopathy 
Cited with permission from Ann Nuclear Cardiol [4]. 
Initial version of the diagnostic criteria: Ann Nucl Cardiol 2018;4:94-100 
Items     Clinical findings
1.Essential items  
Impaired LCFA metabolism or triglyceride deposition in myocardium  
　　　1) Decreased washout rate (<10%) in myocardial 123I-BMIPP SPECT  
　　　2) Myocardial triglyceride deposition by biopsy specimens (a)  
　　　3) Myocardial triglyceride deposition by CT or MR spectroscopy  
2. Major items   
　　　1) Decreased left ventricular ejection fraction (<40%)  
　　　2) Diffuse narrowing of coronary arteries documented by CAG and/or coronary 
CT angiography (b)  
　　　3) Typical Jordans’ anomaly (apparent vacuoles >1µm in size) of 
polymorphonuclear leucocytes in peripheral blood smear (c) 
Diagnosis 
Definite TGCV: One or more essential items and one or more major items are met.  
Probable TGCV: At least one essential item is met.
Supportive items (d)
1) Diabetes mellitus (e)  
　　2) Haemodialysis
(a) For tissue triglyceride contents examination, frozen sections with osmium fixation, 
but not paraffin sections, should be used for prevention of lipid elution
(b) The presence or absence of a significant stenosis is not considered
(c) For difficult cases, May-Giemsa staining slides of peripheral blood smear will be 
evaluated by the Japan TGCV Study Group
(d) These items are commonly present according to autopsy heart analysis and small-
scale cohort analysis performed by the Japan TGCV Study Group but not proven to 
have diagnostic accuracy or causal relationship.
(e) According to the diagnostic criteria of diabetes mellitus by the Japan Diabetes 
Society.





Metabolism of free fatty acid and 123I-BMIPP and typical short-axis 123I-BMIPP images in patients 
with and without TGCV. 
Free fatty acid (FFA) and 123I-BMIPP metabolism (A). Early (15 minutes) and late (3 hours) 123I-
BMIPP mid short-axis images of 35- and 58-year-old men with primary TGCV (B) and aortic 
regurgitation (C), respectively. Actual range of 123I-BMIPP activity is shown as standardised to 
maximum early count of 100%, and decay for 3 hours is corrected. Uptake is similar in the early 
and late images of patient with TGCV (B), but reduced in late image of patient without TGCV (C). 
Calculated washout rates of 123I-BMIPP from whole heart counts were -0.7% and 17%, respectively. 
Original patient information was provided courtesy of Professor Ken-ichi Hirano, Osaka University, 
Japan.  
Abbreviations: AMP, adenosine monophosphate; ATGL, adipose triglyceride lipase; ATP, adenosine 
triphosphate; FFA, free fatty acid; TGCV, triglyceride deposit cardiomyovasculopathy. 
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